OCEANSIDE, NY – October 2009 – elliquence, LLC., a leading medical device designer and manufacturer based in Oceanside, New York, is pleased to announce that it has partnered with Bonovo Orthopedic, Inc. for the distribution of its products in China. Bonovo Orthopedics, Inc. is a premier manufacturer and distributor of quality products to the Chinese orthopedic and neurosurgical communities. Headquartered in United States, Bonovo maintains operations in Beijing, Shanghai and Tianjin, and has distribution offices throughout China.
According to Peter Slate, Chief Executive Officer of Bonovo, “Our partnership with elliquence furthers Bonovo’s commitment to bring the latest minimally invasive products to the Chinese orthopedic and neurosurgical markets. Partnering with innovative partners like elliquence has become a growing component of Bonovo’s business.”
Committed to driving new standards of premium orthopedic care, the Bonovo team will now distribute elliquence products including elliquence’s proprietary energy source; the Patented Surgi-Max®. Emitting high radiofrequency, low-temperature radio waves, the Surgi-Max® enables surgeons to perform delicate, minimally invasive surgery with unparalleled precision, versatility and safety. Bonovo has further enhanced its product portfolio to also include elliquence’s acclaimed Trigger-Flex® Bipolar System (featured in Disc-FX®). Disc-FX rapidly and effectively performs minimally invasive discectomy procedures for contained lumbar spine herniations. elliquence’s latest neurosurgical product offering, the Cappabianca™ Bipolar System will also be featured in Bonovo’s product portfolio. elliquence and Bonovo’s partnership constitutes a commitment to offering products that answer clinical needs of both the surgeon and the patient.
Alan Ellman, Chief Executive Officer of Elliquence states, ” Bonovo Orthopedics is the perfect partner for elliquence’s unique, patented minimally invasive products and we are excited about the potential this relationship offers the patients and physicians in the orthopedic and neurosurgical markets.”